profit from every $100 of sales.
$0$100
SAB Biotherapeutics
We have no price for SAB Biotherapeutics since 22 October 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.00+2.33% today
-93.5% in 1 year
1-year low $0.001-year high $0.02
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What SAB Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with $13.3 million of profit last year.
SalesProfit
SAB Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| SAB Biotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads SAB Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -29 | -38 | -43 | -49 | |
| -15 | -38 | -29 | 17 | |
| -19 | -42 | -34 | 13 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 51 | 84 | 44 | 173 |
| Cash | 15 | 57 | 9 | 11 |
| Total debt | 6 | 6 | 5 | 6 |
| Total liabilities | 20 | 27 | 18 | 21 |
| 31 | 57 | 26 | 151 | |
| – | – | – | – | |
| -39.3% | -52.3% | -87.1% | 6.8% | |
| -60.3% | -73.6% | -131.3% | 8.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -23 | -25 | -34 | -45 | |
| 2 | 0 | 0 | 1 | |
| -26 | -25 | -35 | -46 | |
| Dividends paid | – | – | – | – |
| 6 | 0 | – | – | |
| 3 | 2 | 3 | 5 |
Valuation
- –
- –
- 14.46
- 0.8×
- 0.0×
- –
- 11.1×
- -24,275.1%
- -0.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -24.3%
- -51.3%
- -0.3%
- -0.2%
- -24.4%
- –
Growth
- –
- –
- −32.0%
- –
- +45.2%
Financial health
- -8.2×
- 0.03
- 2.5%
- -248.8×
- 11.45
- 11.45
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 963
Bottom 20%of 894
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.35 | -0.21 | −64.7% |
| Mar 9, 2026 | -0.33 | -0.21 | −54.3% |
| Nov 13, 2025 | 0.58 | -0.46 | +227.4% |
| Aug 13, 2025 | -1.09 | -0.80 | −36.7% |
| May 9, 2025 | -0.56 | – | – |
| Sep 30, 2023 | -0.10 | – | – |
| Jun 30, 2023 | -0.14 | – | – |
| Mar 31, 2023 | -0.15 | – | – |
News
Protalix BioTherapeutics beats top-line and bottom-line estimates; reaffirms FY26 outlookSeeking Alpha · Nov 10, 2026Quant snapshot: Iovance Biotherapeutics and DiamondRock Hospitality Company lead top-rated names as Intact Financial and Fiserv Payments lagSeeking Alpha · Nov 2, 2026Arcutis Biotherapeutics advances 11% to new 52-week highSeeking Alpha · Oct 19, 2026Why Iovance Biotherapeutics Stock Was on Fire TodayYahoo Finance · Sep 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
69Pass
Philip Fisher
28No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
22No pass
Terry Smith
16No pass
Questions about SAB Biotherapeutics
Is SAB Biotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the SAB Biotherapeutics AI analysis
What does SAB Biotherapeutics do?
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It is in Biotechnology.
Does SAB Biotherapeutics pay a dividend?
No. SAB Biotherapeutics does not pay a dividend at the moment.
How has SAB Biotherapeutics stock done over the past year?
Down 93.5% over the past twelve months, to $0.00. It traded between $0.00 and $0.02 and is 95.4% below its high.
Who are SAB Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with SAB Biotherapeutics's.
Prices: daily closes to Oct 22, 2026. Fundamentals: company reports via invest-like data.